Anti-Infectives [1]

The Sandoz Anti-Infectives & API Business Unit is a fully-integrated provider of affordable, high-quality pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms.

From our global headquarters in Kundl, Austria, we ensure excellence in manufacturing across our 10+ state-of-the-art production facilities and on-time delivery to our global network of industrial customers and partners. Production is carried out in accordance with current Good Manufacturing Practices (cGMP) and our facilities have been approved by all major health authorities worldwide, including the European Directorate for the Quality of Medicines (EDQM) and the United States Food and Drug Administration (FDA).

Our strong European production base, close cooperation with Novartis and decades of experience in pharmaceutical development, production and commercialization, make it possible for us to set the industry standards for quality and continuity of supply.

Tab:

Antibiotics [2]

A Global Leader in Antibiotics

As the global leader in generic antibiotics, Sandoz plays a critical role in ensuring the sustainability of global healthcare systems: antibiotics are the cornerstone of healthcare today. In addition to treating a wide range of infectious diseases, antibiotics are critical to guarantee patient safety during in-hospital medical procedures such as transplants.

Sandoz has a rich tradition of providing high-quality antibiotics. We led the way in supplying desperately needed antibiotics to the post-war Austrian population and produced the first ever oral penicillin in 1951. Our commitment to the successful outcomes of patients using our products has elevated us to become one of the world’s biggest producers of antibiotics.

We are proud to offer a comprehensive antibiotic portfolio consisting of Penicillins, Cephalosporins and Macrolides – products that form the backbone of global healthcare. We
are committed to shaping the optimal environment that sustains the effectiveness of all antibiotics.

Overview of Our Antibiotic Business

An investment in the long-term success of this important medicine:

- Sandoz is the largest generic antibiotic manufacturer in the world, with 300 million packs of antibiotics produced annually
- Sandoz owns last remaining production facility in Western Europe, located in Kundl, Austria
- Sandoz is the 3rd largest maker of antibiotics globally and we produce the active pharmaceutical ingredients (API) for other leading companies
- The Sandoz portfolio of antibiotics covers over 50% of the antibiotics available giving us the opportunity to serve a broad majority of today’s antibiotic needs
- Antibiotics is the largest and oldest business at Sandoz

Strong Commitment Advancing Antibiotic Treatment

Our leadership position gives us the opportunity to remind people not only about the importance of antibiotics, but also about using them responsibly, including the best stewardship practices. Growing antimicrobial resistance (AMR) is one of the major threats to global health today. Indeed, the WHO estimates that it could lead to an additional 10 million annual deaths by 2050 if uncontrolled – more than the total number of deaths from all infectious diseases worldwide in 2012 (9.5 million). Sandoz is committed to work with other stakeholders to tackle the root causes of AMR, with a particular focus on increasing understanding of AMR and rational use of antibiotics, promoting the appropriate use of antibiotics (implementation of therapeutic guidelines, for instance on first and second line use, as well as driving prescription-only use), and ensuring stable manufacturing and secure supply.

In addition to producing generic antibiotics, as part of the Novartis Group, we are committed to Novel Antibiotics research to understand mechanisms of occurrence of AMR to identify new targets against the most important nosocomial and opportunistic infections. Novartis also supports the “Innovative Medicines Initiative” of the EU which invests 344 million EUR into antimicrobial resistance measures and activities.
We also support measures for the adoption of novel formulations and incremental Innovations. While novel antibiotics may take years to develop, manufacturers are able to develop new formulations much more quickly. These novel formulations – such as pediatric dosage forms – can help decrease non-adherence to therapy which is also an important cause of AMR.

Through our own Development efforts, Sandoz is actively working to ensure the broadest generic portfolio is always available, providing the opportunity for targeted treatments to match the infection. We plan to add to this portfolio over the next several years.

**API Cooperations** [3]

**Setting Standards in Custom Manufacturing**

Anti-Infectives & API Cooperations offer high-quality custom manufacturing for fermentation-derived and semi-synthetic small molecules.

Our expertise is built upon over 70 years of experience in the production of intermediates and active pharmaceutical ingredients (APIs) across a wide range of therapeutic areas, including highly toxic oncology molecules.

Our leading-edge, global manufacturing network includes a range of fermenter sizes and fully equipped multipurpose synthesis reactors with appropriately scaled downstream lines. Our offering is expertly supported by industry-leading developers who have decades of experience with the development, scale up, transfer, and implementation of processes of varying levels of complexity.

There are many reasons to choose us as your manufacturing partner, including:

- Our in-depth experience and expertise in biotech manufacturing
- Our long and distinguished track record in custom manufacturing
- Our tried and trusted partnership with global pharmaceutical companies
- Our end-to-end expert support throughout the life of a project

For additional information, please contact:
Contact API Cooperations

David Tonin
Head API Franchise
Phone: +43 5338 200 9281
Email: david.tonin@sandoz.com

Portfolio

The mainstays of our product portfolio are the classical fermentation-derived antibiotics, namely: Penicillins, Cephalosporins and Macrolides. Today, we are the largest fully-integrated producer of β-lactam antibiotics in the western world.

Our product portfolio has recently been extended to include other therapeutic areas and to many of our customers, we are a one-stop shop for bulk pharmaceutical intermediates and active pharmaceutical ingredients (APIs). In addition, our partner label service offers customers access to a wide variety of finished dosage forms.

Accordion Type: Collapsible

Source URL: https://www.sandoz.com/our-work/disease-areas/anti-infectives

Links
[4] mailto:david.tonin@sandoz.com